rheumatology dermatology
CASPAR Criteria (Psoriatic Arthritis)
Classification criteria for psoriatic arthritis (PsA) using the CASPAR criteria. Score >=3 with inflammatory articular disease = PsA.
Score interpretation
CASPAR criteria not met for PsA
→ PsA not classified; consider other seronegative arthritis; monitor if psoriasis present
CASPAR criteria met — PsA classified
→ Psoriatic arthritis; DMARDs (methotrexate); biologic if inadequate response (anti-TNF, IL-17i, IL-12/23i); dermatology co-management
Interpretation bands for the CASPAR / PsA. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Deucravacitinib (TYK2 Inhibitor — Psoriatic Arthritis/Psoriasis) · Selective TYK2 Inhibitor (Allosteric — Regulatory Domain Binding)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Salicylic Acid · Keratolytic — Warts / Psoriasis / Hyperkeratosis
- Ixekizumab · IL-17A Inhibitor — Psoriasis
- Guselkumab · IL-23 Inhibitor — Psoriasis
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.